85 citations
,
January 1996 in “International Journal of Cancer” In this study, AS101 combined with chemotherapy significantly reduced the severity of chemotherapy-induced alopecia in non-small-cell-lung-cancer patients and may involve immune mechanisms related to IL-1 and PGE2.
51 citations
,
December 2003 in “The FASEB Journal” This study reports that AS101 induced hair growth in mice and suggests potential for treating chemotherapy-induced alopecia in humans, which was observed in case report studies with three adolescents.
155 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” This review covers various strategies to manage chemotherapy-induced alopecia, highlighting that agents like AS101 and minoxidil can reduce its severity but not prevent it, with no new clinical results reported.
103 citations
,
December 2011 in “Journal of the American Academy of Dermatology” This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.
97 citations
,
September 2006 in “Pharmaceutical Research” This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.